Ads
related to: Abbvie- AbbVie News Center
See Our Achievements, Growth Story,
and More Today.
- Read AbbVie Stories
Read Stories About Our Science,
People, and More Today.
- Investor Resources
Find Financial Reports, Stock Info
And More Resources For Investors.
- Supporting Our Workforce
Embracing Equality & Diversity
Makes Us More Innovative.
- AbbVie News Center
Search results
AbbVie's tight grip on Humira market raises concerns about biosimilars By Reuters
Investing.com· 1 day agoHumira, which lists for almost $7,000 a month, is the first top-selling drug to compete with a slew...
AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges...
Benzinga· 1 day agoAbbVie Inc’s ABBV top-selling arthritis drug, Humira, has managed to retain over 80% of its patients even after facing nine lower-priced rivals in the U.S. over the past year ...
AbbVie's tight grip on Humira market raises concerns about biosimilars
AOL· 1 day agoHumira, which lists for almost $7,000 a month, is the first top-selling drug to compete with a slew of biosimilars, which are close but not exact copies of branded biologic medicines. But after ...
CEREVEL NEWS NOTIFICATION: BFA Law Alerts Cerevel (Nasdaq: CERE) Shareholders of Investigation into...
Benzinga· 11 hours agoNEW YORK, June 08, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) and AbbVie, Inc. If you invested in
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks· 2 days agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 9 hours agoNEW YORK, June 08, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) and AbbVie ...
AbbVie Inc. (NYSE:ABBV) Receives $176.14 Average PT from Brokerages
ETF DAILY NEWS· 5 days agoShares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have earned an average rating of “Moderate Buy” from the fourteen ratings firms that are presently covering the stock, ...
AbbVie's ovarian cancer therapy succeeds in mid-stage trial
Reuters· 2 days agoThe U.S. Food and Drug Administration had in March approved the treatment for use in patients with...
AbbVie Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU - AbbVie (NYSE:ABBV), ALX Oncology...
Benzinga· 5 days agoAbbVie ABBV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...
California State Teachers Retirement System Acquires 42,587 Shares of AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 5 days agoCalifornia State Teachers Retirement System raised its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 1.5% in the 4th quarter, according to the company in ...
Ad
related to: Abbvie